Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect and Safety of Combination Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients
Brief Summary: A prospective, randomized, controlled open clinic trial to evaluate the effect and safety of combination of conventional hemodialysis(HD) and hemoperfusion(HP) on middle molecules removal and complications improvement in long-term maintenance hemodialysis (MHD) patients.

There are two phases of study for each subject. Phase 1 (screening phase). During this phase, each potential subject will be evaluated to determine if he/she is eligible for the study.

Phase 2 (intervention phase). Each subject will be randomly allocated to HD+HP(HA130 once per week) group ,HD+HP(HA330 once per week) group and HD group. The follow-up duration was 3 months.


Options:
A: Arm Label: NB-UVB; Type: EXPERIMENTAL; Interventions: Device: Narrow band UVB phototherapy , long wave UVA phototherapy | Arm Label: UVA; Type: PLACEBO_COMPARATOR; Interventions: Device: Narrow band UVB phototherapy , long wave UVA phototherapy | Intervention Type: DEVICE; Name: Narrow band UVB phototherapy , long wave UVA phototherapy; Assigned to Arm(s): NB-UVB, UVA
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine HCl 2.5 µg | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine HCl 5.0 µg | Intervention Type: DRUG; Name: Nalfurafine HCl 2.5 µg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Nalfurafine HCl 5.0 µg; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MT-9938 2.5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 2.5μg | Arm Label: MT-9938 5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 5μg | Arm Label: MT-9938 10μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 10μg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 2.5μg; Assigned to Arm(s): MT-9938 2.5μg | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 5μg; Assigned to Arm(s): MT-9938 5μg | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 10μg; Assigned to Arm(s): MT-9938 10μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: hemodialysis+hemoperfusion (HA330); Type: EXPERIMENTAL; Interventions: Other: hemodialysis only, Other: hemodialysis plus hemoperfusion(HA330) | Arm Label: hemodialysis+hemoperfusion (HA130); Type: EXPERIMENTAL; Interventions: Other: hemodialysis only, Other: hemodialysis plus hemoperfusion(HA130) | Arm Label: hemodialysis only; Type: ACTIVE_COMPARATOR; Interventions: Other: hemodialysis only | Intervention Type: OTHER; Name: hemodialysis only; Assigned to Arm(s): hemodialysis only, hemodialysis+hemoperfusion (HA130), hemodialysis+hemoperfusion (HA330) | Intervention Type: OTHER; Name: hemodialysis plus hemoperfusion(HA330); Assigned to Arm(s): hemodialysis+hemoperfusion (HA330) | Intervention Type: OTHER; Name: hemodialysis plus hemoperfusion(HA130); Assigned to Arm(s): hemodialysis+hemoperfusion (HA130)

Answer: D